The company generated $62.5 million in annual revenue in 2026, positioning it as a specialized ADHD-focused pharmaceutical company. Neos is advancing clinical-stage pipeline with NT0502 for the treatment of sialorrhea in patients with neurological conditions, though its core business remains ADHD products and generic cough/cold formulations.
Cyborg Score Rationale
Neos operates as a niche pharmaceutical company with established ADHD products generating near-$63M revenue, but faces significant headwinds. Market cap of $57M is less than annual revenue, signaling investor concern. The company operates with only 15 employees, suggesting a lean operation with limited R&D capacity. Pipeline progress is stalled with NT0502 still in clinical-stage development.
Top Insights
Generated $62.5M revenue in 2026 with only 15 employees, indicating operational efficiency but potential capacity constraints for scaling or pipeline advancement.
Market cap of $57.23M as of May 2026 sits below trailing revenue, reflecting investor skepticism about growth prospects or profitability trajectory despite established product commercialization.
NT0502 clinical-stage candidate for sialorrhea remains in early development, suggesting limited near-term pipeline catalysts beyond existing ADHD and generic product monetization.
Named Competitors
Cingulate Inc. — ADHD treatment competitor
Adlon Therapeutics — ADHD treatment developer
Aytu BioPharma — Extended-release ADHD medications including Cotempla XR-ODT competitor
Naurex — CNS disorder and ADHD treatment developer
Recent Developments
(May 2026) Market cap assessed at $57.23M
(February 2026) Pipeline data updated, NT0502 clinical trial status confirmed
(January 2026) Funding history reviewed; no new capital raises since May 2016
Open the full interactive Neos Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.